• Explore /
  • Poster
  • / A phase I/II, open label, single arm study on safety, tolerability and anti-tumour effiacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma.

A phase I/II, open label, single arm study on safety, tolerability and anti-tumour effiacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma.

Abstract Poster

Authors

null

Sven Lundstam

Departments of Oncology and Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Sven Lundstam , Boerje Haraldsson , Jenny Nystrom , Jeffrey Yachnin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05287945

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS486)

DOI

10.1200/JCO.2024.42.4_suppl.TPS486

Abstract #

TPS486

Poster Bd #

M7

Abstract Disclosures

Similar Posters

Poster

2014 Genitourinary Cancers Symposium

A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer.

A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer.

First Author: Amanda Marie Fitzpatrick

First Author: H. M. Vankayala

First Author: Charles B. Nguyen

First Author: Geoffrey Johnson